JP2017508475A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508475A5
JP2017508475A5 JP2016559286A JP2016559286A JP2017508475A5 JP 2017508475 A5 JP2017508475 A5 JP 2017508475A5 JP 2016559286 A JP2016559286 A JP 2016559286A JP 2016559286 A JP2016559286 A JP 2016559286A JP 2017508475 A5 JP2017508475 A5 JP 2017508475A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508475A (ja
JP6865585B2 (ja
Filing date
Publication date
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Application filed filed Critical
Priority claimed from PCT/EP2015/056654 external-priority patent/WO2015144855A1/en
Publication of JP2017508475A publication Critical patent/JP2017508475A/ja
Publication of JP2017508475A5 publication Critical patent/JP2017508475A5/ja
Priority to JP2021064572A priority Critical patent/JP7607498B2/ja
Application granted granted Critical
Publication of JP6865585B2 publication Critical patent/JP6865585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559286A 2014-03-26 2015-03-26 成長分化因子15(gdf−15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 Active JP6865585B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021064572A JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB1405475.3 2014-03-26
GB1405477.9 2014-03-26
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064572A Division JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Publications (3)

Publication Number Publication Date
JP2017508475A JP2017508475A (ja) 2017-03-30
JP2017508475A5 true JP2017508475A5 (enExample) 2018-05-17
JP6865585B2 JP6865585B2 (ja) 2021-04-28

Family

ID=52745885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016559286A Active JP6865585B2 (ja) 2014-03-26 2015-03-26 成長分化因子15(gdf−15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021064572A Active JP7607498B2 (ja) 2014-03-26 2021-04-06 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2023062338A Withdrawn JP2023098966A (ja) 2014-03-26 2023-04-06 成長分化因子15(gdf-15)に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用

Country Status (22)

Country Link
US (6) US20170204174A1 (enExample)
EP (3) EP3122775B1 (enExample)
JP (3) JP6865585B2 (enExample)
KR (1) KR102520978B1 (enExample)
CN (1) CN106536553B (enExample)
AU (2) AU2015238264B2 (enExample)
BR (1) BR122023027559A2 (enExample)
CY (1) CY1122456T1 (enExample)
DK (2) DK3653644T5 (enExample)
ES (2) ES2965626T3 (enExample)
FI (1) FI3653644T3 (enExample)
HR (2) HRP20231514T1 (enExample)
HU (2) HUE047398T2 (enExample)
IL (2) IL248038B (enExample)
LT (2) LT3653644T (enExample)
NZ (1) NZ724649A (enExample)
PL (2) PL3653644T3 (enExample)
PT (2) PT3653644T (enExample)
RS (1) RS59700B1 (enExample)
SI (1) SI3122775T1 (enExample)
SM (1) SMT202000064T1 (enExample)
WO (1) WO2015144855A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023027559A2 (pt) 2014-03-26 2024-01-30 Julius-Maximilians-Universität Würzburg Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
CA3000290C (en) * 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
HRP20221530T1 (hr) * 2015-10-02 2023-03-17 Julius-Maximilians-Universität Würzburg Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke
CN109071647B (zh) * 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
AU2017293450B2 (en) * 2016-07-06 2024-08-08 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
CA3038846A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
US20200069774A1 (en) * 2016-12-06 2020-03-05 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
TWI803682B (zh) * 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗-gdf15抗體、組成物及使用方法
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
MX2023011655A (es) 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
CA3250445A1 (en) * 2022-01-26 2025-03-10 Yunnan Baiyao Group Co., Ltd. ANTIBODY MOLECULE DIRECTED AGAINST DIFFERENTIATION AND GROWTH FACTOR 15 AND ITS USE
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神(北京)生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
TW202547861A (zh) * 2024-04-23 2025-12-16 大陸商勁方醫藥科技(上海)股份有限公司 抗gdf-15抗體及其應用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO2000070051A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
DK2311873T3 (en) * 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
PT2441466E (pt) * 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 il17 에 대한 항체 및 이의 용도
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP6013915B2 (ja) * 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
CN104853775B (zh) * 2012-09-26 2023-10-20 尤利乌斯·马克西米利安维尔茨堡大学 针对生长和分化因子15(gdf-15)的单克隆抗体
MX370720B (es) 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
BR122023027559A2 (pt) 2014-03-26 2024-01-30 Julius-Maximilians-Universität Würzburg Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos

Similar Documents

Publication Publication Date Title
JP2017508475A5 (enExample)
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
NZ740686A (en) Therapeutic cd47 antibodies
MX2024005027A (es) Anticuerpos de union a cd3.
EA201791270A1 (ru) Модифицированные april-связывающие антитела
NZ610734A (en) Human antibodies to the glucagon receptor
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
MX392340B (es) Anticuerpo anti cd73 humana.
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
AR105724A1 (es) Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
JOP20200161B1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
RU2016100892A (ru) Антитела против tweakr и их применение
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид